RSS-Feed abonnieren
DOI: 10.1055/a-2157-2944
Predictors and Trends in First-Trimester Hemoglobin A1c Screening in New York City, 2009 to 2017
Funding This study was funded by the National Institutes of Health, grant no.: R21DK122266.Abstract
Glycated hemoglobin is an adjunct tool in early pregnancy to assess glycemic control. We examined trends and maternal predictors for those who had A1c screening in early pregnancy using hospital discharge and vital registry data between 2009 and 2017 linked with the New York City A1C Registry (N = 798,312). First-trimester A1c screening increased from 2.3% in 2009 to 7.7% in 2017. The likelihood of screening became less targeted to high-risk patients over time, with a decrease in mean A1c values from 5.8% (95% confidence interval [CI]: 5.8, 5.9) to 5.3 (95% CI: 5.3, 5.4). The prevalence of gestational diabetes mellitus increased while testing became less discriminate for those with high-risk factors, including pregestational type 2 diabetes, chronic hypertension, obesity, age over 40 years, as well as Asian or Black non-Hispanic race/ethnicity.
Key Points
-
First-trimester A1c screening increased from 2.3% in 2009 to 7.7% in 2017 in New York City.
-
The likelihood of screening became less targeted to high-risk patients over time.
-
The prevalence of gestational diabetes mellitus increased, while testing became less discriminate.
Keywords
first-trimester hemoglobin A1c screening - pregestational diabetes - A1c screening - hemoglobin A1cPrecis
First-trimester hemoglobin A1C screening has increased from 2009 to 2017, while testing became less discriminate for those with high-risk factors in pregnancy.
Publikationsverlauf
Eingereicht: 02. Januar 2023
Angenommen: 17. August 2023
Accepted Manuscript online:
21. August 2023
Artikel online veröffentlicht:
29. September 2023
© 2023. Thieme. All rights reserved.
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
-
References
- 1 Fong A, Serra AE, Gabby L, Wing DA, Berkowitz KM. Use of hemoglobin A1c as an early predictor of gestational diabetes mellitus. Am J Obstet Gynecol 2014; 211 (06) 641.e1-641.e7
- 2 Griffiths RJ, Vinall PS, Stickland MH, Wales JK. Haemoglobin A1c levels in normal and diabetic pregnancies. Eur J Obstet Gynecol Reprod Biol 1987; 24 (03) 195-200
- 3 Kiefer MK, Finneran MM, Ware CA. et al. Association of change in haemoglobin A1c with adverse perinatal outcomes in women with pregestational diabetes. Diabet Med 2022; 39 (07) e14822
- 4 American Diabetes Association Professional Practice Committee. 2. Classification and Diagnosis of Diabetes: standards of medical care in diabetes-2022. Diabetes Care 2022; 45 (Suppl. 01) S17-S38
- 5 ACOG Practice Bulletin No. ACOG Practice Bulletin No. 190: gestational diabetes mellitus. Obstet Gynecol 2018; 131 (02) e49-e64
- 6 Wexler DJ, Powe CE, Barbour LA. et al. Research gaps in gestational diabetes mellitus: executive summary of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop. Obstet Gynecol 2018; 132 (02) 496-505
- 7 Association AD. American Diabetes Association. 14. Management of Diabetes in Pregnancy: standards of medical care in diabetes-2021. Diabetes Care 2021; 44 (Suppl. 01) S200-S210
- 8 Davidson KW, Barry MJ, Mangione CM. et al; US Preventive Services Task Force. Screening for gestational diabetes: US Preventive Services Task Force Recommendation Statement. JAMA 2021; 326 (06) 531-538
- 9 Deputy NP, Kim SY, Conrey EJ, Bullard KM. Prevalence and changes in preexisting diabetes and gestational diabetes among women who had a live birth—United States, 2012-2016. MMWR Morb Mortal Wkly Rep 2018; 67 (43) 1201-1207
- 10 Shah NS, Wang MC, Freaney PM. et al. Trends in gestational diabetes at first live birth by race and ethnicity in the US, 2011-2019. JAMA 2021; 326 (07) 660-669
- 11 Hughes RC, Moore MP, Gullam JE, Mohamed K, Rowan J. An early pregnancy HbA1c ≥5.9% (41 mmol/mol) is optimal for detecting diabetes and identifies women at increased risk of adverse pregnancy outcomes. Diabetes Care 2014; 37 (11) 2953-2959